Hi Phaedrus,We should catch up at the AGM!I think SI hasn’t been...

Hi Phaedrus,

We should catch up at the AGM!

I think SI hasn’t been transparent and I’m comparing him with a couple of small caps and mid to large US cap companies.

‘I’m referring to finance. Like the last few CR. The following;

subject to approval. $50mil USD-2024

• Hiring of select senior positions to build targeted commercial team has commenced.• Key Pre-Launch Activities include Market Access initiates payer outreacho Medical provides education to payerso Corporate leadership initiates engagement with Top 15 centerso Regional sales directors lead center profilingo Ongoing KOL engagement with greatest experience using RYONCIL at highest volumecenterso Non-promotional activities including profiling high-volume centers, education on diseaseawareness & unmet needs, and payer engagement• Post-launch - Staged approach based on centers with highest volume and experience with product.• Targeted sales force with experience in bone marrow transplant centers - 15 highest volume centersaccount for ~50% of patients.

$36milAUD- Dec 2023

Use of ProceedsProceeds from the Placement and Entitlement Offer and existing cash reserves will be used to fund theadult Phase 3 registration trials for steroid-refractory acute-graft versus host disease and for chroniclower back pain, and general corporate purposes.

$40mil USD-April 2023

Proceeds will be used to fund:• Launch and commercialization of the company’s lead product, remestemcel-L, in the treatmentof children with steroid-refractory acute graft versus host disease (SR-aGVHD) subject toapproval by the US Food & Drug Administration (FDA) of Mesoblast’s resubmitted BiologicsLicense Application (BLA) which has a PDUFA goal date of August 2, 2023.• Ongoing manufacturing of commercial remestemcel-L product at the Lonza Biosciences facilityin Singapore, where the upcoming scheduled pre-licensure inspection (PLI) will be performedby FDA.• Initiation of patient enrolment in the confirmatory Phase 3 clinical trial of rexlemestrocel-L forchronic low back pain associated with degenerative disc disease.

This is a total of 114mil USD in 18 months.

I need to note: CR back in 2020 just before CRL was for the purposes of ‘the launch and commercialisation of aGVHD’


As a shareholder, I could not work out where the money was spent, since MSB received two CRL’s. I would have put the money for commercial purposes in a savings account. lol. the Greek in me! Maybe you or someone else can help with this.

This is the reason why i’m 50/5- in the trust category. Any other time I would have sold long time ago. The reason I’m still in i trust him with the science and he seems to bring in money which tells me he has a lot of support in the medical space. It seems his peers trust him and I’m good with that.

if this was another bio, gonski by now! As you know, bio’s consume billions.